Compound Detail
CHEMBL1308
FOMEPIZOLE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL1308 |
| Name | FOMEPIZOLE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | RIKMMFOAQPJVMX-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
1
Targets
2
Activities
2
Assay Types
0
PK Parameters
20
Publications
6
Known Names
1
Indications
1
Mechanisms
Molecular Properties
82.1
MW (Da)
0.72
ALogP
1
HBA
1
HBD
28.7
PSA (Ų)
0.49
QED
0
Ro5 Violations
0
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1997 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Alcohol dehydrogenase class I inhibitor | INHIBITOR | Alcohol dehydrogenase class I | ✓ | ✓ |
Indications
Macular Degeneration
ATC Classification
V03AB34
fomepizole
Level 1: VARIOUS
Level 2: ALL OTHER THERAPEUTIC PRODUCTS
Activity Summary
Kd 1 meas. best 7.89
Ki 1 meas. best 6.85
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Alcohol dehydrogenase CHEMBL2111372 | Kd | 7.89 | 7.89 | 13.0 | 1 |
| Alcohol dehydrogenase CHEMBL2111372 | Ki | 6.85 | 6.85 | 141.2 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Alcohol dehydrogenase | Kd | = | 13.0 | nM | 7.89 | Inhibition of horse liver alcohol dehydrogenase using ethanol as substrate asses... | 219196 |
| Alcohol dehydrogenase | Ki | = | 141.25 | nM | 6.85 | Inhibitory activity against horse liver alcohol dehydrogenase (ADH) | 2939242 |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.6019/CHEMBL3885881 | Rattus norvegicus | 270 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| 20014752 | 10.1021/tx900326k | Hepatotoxicity | 3 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Mu-type opioid receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Gamma-aminobutyric acid receptor subunit alpha-1 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 1A | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2A | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-2A adrenergic receptor | 2 |
| 26948801 | 10.1016/j.drudis.2016.02.015 | Homo sapiens | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Progesterone receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2B | 2 |
| 2939242 | 10.1021/jm00155a005 | Alcohol dehydrogenase | 1 |
| - | 10.6019/CHEMBL4495564 | Replicase polyprotein 1ab | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Voltage-gated inwardly rectifying potassium channel KCNH2 | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Voltage-dependent L-type calcium channel subunit alpha-1C | 1 |
| 38318365 | 10.1016/j.isci.2024.108907 | Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 | 1 |
| - | 10.1101/2020.04.03.023846 | SARS-CoV-2 | 1 |
Data from ChEMBL 36 via Core Engine